CompletedInterventionalPhase 4Last updated Dec 15, 2010

Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814

A Phase IV, Open Label, Single Arm, Multicenter, Extension Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814

Overview

ClinicalTrials.gov ID: NCT00403585
Lead Sponsor: GlaxoSmithKlineINDUSTRY
Brief Summary: This is an open label, single-arm, multi-centre extension study for Korean patients with chronic hepatitis B and compensated liver disease who have completed one-year adefovir dipivoxil treatment in ADF103814. The objective is to assess clinical efficacy and safety of long term (up to 3 years) adefovir dipivoxil 10mg therapy.
Study Type

Status

Overall Status: Completed
Start Date: Jul 2006
Primary Completion Date: Apr 2008Actual
Completion Date: Apr 2008Actual

Study Record Dates

First Submitted: Nov 23, 2006
First Submitted that Met QC Criteria: Nov 23, 2006
First Posted: Nov 27, 2006Estimated
Last Update Submitted that Met QC Criteria: Nov 24, 2010
Last Update Posted: Dec 15, 2010Estimated
Last Verified: Nov 2010

NCT01205165Completed

An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB)

NCT00324961Completed

Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B

NCT00441974Completed

Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients

NCT00857675Completed

A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B

NCT00347009Completed

Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis

NCT00071201Completed

Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B